(Q38059909)

28 August 2017

Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation (English)

1 reference

28 August 2017

0 references

3

1 reference

28 August 2017

John W Eikelboom

2

0 references

author name string

Mark J Alberts

series ordinal

1

1 reference

28 August 2017

1 December 2012

1 reference

28 August 2017

1 reference

28 August 2017

11

1 reference

28 August 2017

12

1 reference

28 August 2017

1066-1081

1 reference

2011 ACCF/AHA/HRS Focused Updates Incorporated Into the ACC/AHA/ESC 2006 Guidelines for the Management of Patients With Atrial Fibrillation

28 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Newly identified events in the RE-LY trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Rivaroxaban versus warfarin in nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Apixaban versus warfarin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Apixaban in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

The global burden of atrial fibrillation and stroke: a systematic review of the epidemiology of atrial fibrillation in regions outside North America and Europe

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Screening versus routine practice in detection of atrial fibrillation in patients aged 65 or over: cluster randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Trends in the prevalence of diagnosed atrial fibrillation, its treatment with anticoagulation and predictors of such treatment in UK primary care

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Atrial fibrillation as an independent risk factor for stroke: the Framingham Study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Comparison of the impact of atrial fibrillation on the risk of stroke and cardiovascular death in women versus men (The Copenhagen City Heart Study)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Mortality trends in patients diagnosed with first atrial fibrillation: a 21-year community-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Outcomes for patients with ischaemic stroke and atrial fibrillation: the PRISM study (A Program of Research Informing Stroke Management)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Time trends of ischemic stroke incidence and mortality in patients diagnosed with first atrial fibrillation in 1980 to 2000: report of a community-based study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Atrial fibrillation and stroke in the general medicare population: a 10-year perspective (1992 to 2002).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Reliable identification of "truly low" thromboembolic risk in patients initially diagnosed with "lone" atrial fibrillation: the Belgrade atrial fibrillation study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

A 12-year follow-up study of patients with newly diagnosed lone atrial fibrillation: implications of arrhythmia progression on prognosis: the Belgrade Atrial Fibrillation study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Independent predictors of stroke in patients with atrial fibrillation: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Current status of stroke risk stratification in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Statistical evaluation of prognostic versus diagnostic models: beyond the ROC curve

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Statistical methods for the assessment of prognostic biomarkers (Part I): discrimination.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Validation of Clinical Classification Schemes for Predicting Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

The CHADS2 score for stroke risk stratification in atrial fibrillation--friend or foe?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Can we predict stroke in atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Performance of stroke risk scores in older people with atrial fibrillation not taking warfarin: comparative cohort study from BAFTA trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Stroke risk stratification in a "real-world" elderly anticoagulated atrial fibrillation population

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Additive role of plasma von Willebrand factor levels to clinical factors for risk stratification of patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Disparate stroke rates on warfarin among contemporaneous cohorts with atrial fibrillation: potential insights into risk from a comparative analysis of SPORTIF III versus SPORTIF V.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Can patients at elevated risk of stroke treated with anticoagulants be further risk stratified?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Identifying patients at high risk for stroke despite anticoagulation: a comparison of contemporary stroke risk stratification schemes in an anticoagulated atrial fibrillation cohort

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Validation of the CHADS2 clinical prediction rule to predict ischaemic stroke. A systematic review and meta-analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

A comparison of risk stratification schemes for stroke in 79,884 atrial fibrillation patients in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Sex differences in stroke risk among older patients with recently diagnosed atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Performance of the HEMORR(2)HAGES, ATRIA, and HAS-BLED bleeding risk-prediction scores in patients with atrial fibrillation undergoing anticoagulation: the AMADEUS (evaluating the use of SR34006 compared to warfarin or acenocoumarol in patients with

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Racial/ethnic differences in the risk of intracranial hemorrhage among patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Influence of CYP2C9 and VKORC1 1173C/T genotype on the risk of hemorrhagic complications in African-American and European-American patients on warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Stroke and Bleeding in Atrial Fibrillation with Chronic Kidney Disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention In Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) study groups.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Cerebral microbleeds: a guide to detection and interpretation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Cerebral microbleeds in ischemic stroke patients on warfarin treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Efficacy and Safety of Anticoagulant Treatment in Acute Cardioembolic Stroke: A Meta-Analysis of Randomized Controlled Trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Effect of clopidogrel added to aspirin in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W).

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Anticoagulation control and prediction of adverse events in patients with atrial fibrillation: a systematic review

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Use and effectiveness of warfarin in Medicare beneficiaries with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Worldwide management of oral anticoagulant therapy: the ISAM study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Novel oral factor Xa and thrombin inhibitors in the management of thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

New oral anticoagulants: a view from the laboratory

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran etexilate: a new oral thrombin inhibitor

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939--an oral, direct Factor Xa inhibitor--after multiple dosing in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Metabolism and excretion of rivaroxaban, an oral, direct factor Xa inhibitor, in rats, dogs, and humans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Apixaban, an oral, direct and highly selective factor Xa inhibitor: in vitro, antithrombotic and antihemostatic studies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Apixaban metabolism and pharmacokinetics after oral administration to humans

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Evaluation of the novel factor Xa inhibitor edoxaban compared with warfarin in patients with atrial fibrillation: design and rationale for the Effective aNticoaGulation with factor xA next GEneration in Atrial Fibrillation-Thrombolysis In Myocardial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Anticoagulation therapy. Dabigatran and risk of myocardial infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Apixaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of the ARISTOTLE trial

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Comparative efficacy and safety of new oral anticoagulants in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Adjusted indirect comparison of new oral anticoagulants for stroke prevention in atrial fibrillation.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Systematic review and adjusted indirect comparison meta-analysis of oral anticoagulants in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

What do the results of the PRoFESS trial teach us?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Anticoagulant options--why the FDA approved a higher but not a lower dose of dabigatran

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran efficacy-safety assessment for stroke prevention in patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Microbleeds are associated with subsequent hemorrhagic and ischemic stroke in healthy elderly individuals.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Medication adherence: its importance in cardiovascular outcomes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Adherence to medicines in the older-aged with chronic conditions: does intervention by an allied health professional help?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Coagulation parameters in patients receiving dabigatran etexilate or rivaroxaban: two observational studies in patients undergoing total hip or total knee replacement

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

The International Normalized Ratio calibrated for rivaroxaban has the potential to normalize prothrombin time results for rivaroxaban-treated patients: results of an in vitro study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Laboratory assessment of new anticoagulants

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

New direct oral anticoagulants--current therapeutic options and treatment recommendations for bleeding complications

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Impact of dabigatran on a large panel of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

An optimised, rapid chromogenic assay, specific for measuring direct factor Xa inhibitors (rivaroxaban) in plasma

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Assays for measuring rivaroxaban: their suitability and limitations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Measuring the anticoagulant effect of direct factor Xa inhibitors. Is the anti-Xa assay preferable to the prothrombin time test?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Guidelines for the Early Management of Adults With Ischemic Stroke

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Fibrinolytic treatment of acute ischemic stroke for patients on new oral anticoagulant drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Acute stroke management in patients taking dabigatran.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Using dabigatran in patients with stroke: a practical guide for clinicians

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Neurothrombectomy devices for the treatment of acute ischemic stroke: state of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Guidance on the emergent reversal of oral thrombin and factor Xa inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Safety of recombinant activated factor VII in randomized clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Cost-effectiveness of dabigatran for stroke prophylaxis in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

Cost-effectiveness of apixaban vs warfarin for secondary stroke prevention in atrial fibrillation

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2812%2970258-2

7 January 2021

10.1016/S1474-4422(12)70258-2

Identifiers

DOI

1 reference

28 August 2017

1 reference

PubMed ID

23153406